NCT04460079View on ClinicalTrials.gov

Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN

CompletedOBSERVATIONAL
Enrollment

654

Participants

Timeline

Start Date

March 29, 2016

Primary Completion Date

September 7, 2019

Study Completion Date

September 7, 2019

Conditions
Chemotherapy-induced Neutropenia
Interventions
DRUG

Peg-filgrastim

PegaGen® was injected as a single subcutaneous dose after completion of cytotoxic chemotherapy

Sponsors

Lead Sponsor

Cinnagen
All Listed Sponsors
lead

Cinnagen

INDUSTRY